CIBC Bancorp USA’s Madrigal Pharmaceuticals MDGL Stock Holding History

CIBC Bancorp USA’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-916	Closed	-$479K	–	1998
2026 Q1	$479K	Buy	+916	New	+$438K	﹤0.01%	1243
2025 Q3	$910K	Buy	+1,983	New	+$740K	0.01%	697

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CIBC Bancorp USA's MDGL Position: Q2 2026 in Review

CIBC Bancorp USA sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 916 shares — an estimated $479K sold.

CIBC Bancorp USA first reported a position in MDGL in Q3 2025 and held it in 2 quarters. The position peaked at $910K in Q3 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

CIBC Bancorp USA reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
CIBC Bancorp USA sold 916 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $479K.
CIBC Bancorp USA first reported a position in Madrigal Pharmaceuticals in Q3 2025 and held it in 2 quarters.
CIBC Bancorp USA's Madrigal Pharmaceuticals position peaked at $910K in Q3 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.